Clinical trials: Anlotinib
Colorectal Cancer, Immunotherapy
Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)
This study is designed to evaluate the efficacy and safety of the combination of Anlotinib and Sintilimab in advanced colorectal cancer as first-line treatment.
- Conditions
- Colorectal Cancer, Immunotherapy, Anlotinib, Sintilimab
- Trial name
- NCT04271813
- Testing
- Anlotinib plus Sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Changzheng Hospital
Proteinuria
Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients
This study is a prospective, multicenter, parallel-controlled clinical trial designed to evaluate the therapeutic efficacy of Huaier Granules for proteinuria occurring in lung cancer patients undergoing treatment with either…
- Trial name
- NCT07358520
- Testing
- Huaier Granule, Anlotinib and Bevacizumab
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Breast Cancer
Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed
This Phase II study was designed to assess the efficacy and safety of the combination of PD-1 inhibitor, Tucidinostat (chidamide), a histone deacetylase inhibitor, and anlotinib in advanced breast cancer.
- Trial name
- NCT06547476
- Testing
- Tucidinostat (chidamide), PD-1 inhibitor (tislelizumab), anlotinib
- Volunteers
- 40 people
- Sponsor
- Guangdong Provincial People's Hospital
Metastatic Colorectal Cancer
A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer
This is an open label, randomized, phase Ⅲ study to treat subjects with RAS/BRAF wild-type, unresectable metastatic colorectal cancer.
- Trial name
- NCT04854668
- Testing
- Anlotinib hydrochloride capsule, Bevacizumab, Oxaliplatin
- Where
- 92 sites in China
- Volunteers
- 748 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Cervical Cancer
Combination Therapy for First Line Treatment of Advanced Cervical Cancer
This is a single center phase 1 trail to observe safety and efficacy of Paclitaxel plus Cisplatin\Carboplatin, PD-L1 antibody Toripalimab and Anlotinib as first-line regimen to treat the patient with metastatic 、persistent or…
- Trial name
- NCT04731038
- Testing
- Anlotinib, Toripalimab, Paclitaxel, Cisplatin/ Carboplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
ESCC
Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)
This study aims to explore the efficacy and safety of anlotinib combined with bemocizumab as neoadjuvant therapy for resectable esophageal squamous cell carcinoma, with the goal of improving the pathological complete response…
- Trial name
- RAOS (NCT07627347)
- Testing
- anlotinib+bevacizumab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Soft Tissue Sarcoma
A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma
A multicenter, randomized, double-blind, parallel-controlled Phase III trial to evaluate the efficacy and safety of anotinib hydrochloride capsule combined with epirubicin hydrochloride versus placebo combined with epirubicin…
- Trial name
- NCT05121350
- Testing
- Anlotinib hydrochloride capsule, Epirubicin
- Where
- 3 sites in China
- Volunteers
- 256 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
HER 2 Negative Breast Cancer
A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates
This study is looking at a new combination of two drugs-eribulin and anlotinib-for patients with HER2-negative advanced breast cancer.
- Trial name
- MBC-EA (NCT07520760)
- Testing
- Eribulin in Combination with Anlotinib
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sun Yat-sen University
Intrahepatic Cholangiocarcinoma
Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic Cholangiocarcinoma
This study will evaluate the efficacy and safety of cryoablation combined with Anlotinib plus TQB2868 in patients with advanced Intrahepatic Cholangiocarcinoma (ICC) who have progressed after first-line treatment.
- Trial name
- CASTLE-ZS-05 (NCT07846267)
- Testing
- Anlotinib, TQB2868 Injection, cryoablation
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Fudan University
SCLC, Maintenance Treatment
Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell
This is a randomized, open, multicenter Phase III clinical study. A total of 136 participants are planned to be enrolled and randomly assigned to either the experimental group (platinum+etoposide → toripalimab plus anlotinib) or…
- Trial name
- SCLC (NCT06441344)
- Testing
- Toripalimab plus Anlotinib, Toripalimab
- Volunteers
- 136 people
- Sponsor
- Taizhou Hospital
Squamous Non-small Cell Lung Cancer
Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer
Anlotinib hydrochloride is a multi-targeted receptor tyrosine kinase inhibitor that targets angiogenesis-related kinases such as VEGFR1/2/3, FGFR1/2/3, and other tumor-associated kinases involved in cell proliferation such as…
- Trial name
- NCT04073537
- Testing
- Anlotinib, Paclitaxel, Carboplatin
- Where
- 2 sites in China
- Volunteers
- 386 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Sarcoma
Anlotinib Hydrochloride Combined With Liposomal Doxorubicin in the Treatment of Locally Advanced or Metastatic Soft Tissue Sarcoma
The investigators explored the activity of anlotinib combined with Liposomal Doxorubicin in patients with Locally Advanced or Metastatic Soft Tissue Sarcoma
- Trial name
- ALTER-S001 (NCT03880695)
- Testing
- Anlotinib+ Liposomal Doxorubicin
- Where
- 8 sites in China
- Volunteers
- 48 people
- Sponsor
- Peking University People's Hospital
Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma
A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
The goal of this interventional study is to compare the safety and efficacy of neoadjuvant immunotherapy plus chemotherapy and anlotinib versus immunotherapy combined with concurrent chemoradiotherapy in the treatment of locally…
- Trial name
- NCT06354530
- Testing
- anlotinib, Thoracic radiotherapy
- Where
- China
- Volunteers
- 266 people
- Sponsor
- Army Medical Center of PLA
Platinum-resistant Recurrent Clear Cell Ovarian Cancer
Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.
According to the definition of National Comprehensive Cancer Network (NCCN), ovarian clear cell carcinoma (OCCC) is a less common subtype of epithelial ovarian cancer (EOC) .
- Trial name
- CC-ANNIE (NCT05130515)
- Testing
- Niraparib, Anlotinib
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nasopharyngeal Carcinoma
Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to explore the efficacy and safety of a combination of GP chemotherapy and Penpulimab ± Anlotinib in neoadjuvant therapy combined with Penpulimab in adjuvant therapy of locoregionally advanced…
- Trial name
- NCT05193617
- Testing
- GP+Penpulimab+Anlotinib, GP+Penpulimab
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Sun Yat-sen University
Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma)
Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors
This is a prospective, single-center, single-arm interventional trial conducted at Tianjin Medical University Cancer Institute and Hospital.
- Trial name
- NCT07444918
- Testing
- Liposomal Irinotecan, Vincristine, Temozolomide, and Optional Anlotinib
- Volunteers
- 33 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Progression Free Survival(PFS)
Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment of Elderly Patients With Small Cell Lung Cancer/ Open-label, Single-arm, Exploratory Phase II Clinical Study
This study aims to explore the safety and efficacy of etoposide capsules combined with Anlotinib and Envafolimab in elderly patients with extensive small cell lung cancer.This is a single-center, single-arm exploratory clinical…
- Trial name
- NCT05685550
- Testing
- Toposide capsules combined with Anlotinib and Envafolimab group
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Melanoma
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
The purpose of this study is to evaluate the efficacy and safety of recombinant human interferon-α1b (IFN-α1b) combined with toripalimab and anlotinib hydrochloride in patients with unresectable advanced melanoma.
- Trial name
- NCT05539118
- Testing
- Recombinant human interferon α1b, Toripalimab, Anlotinib hydrochloride
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Xijing Hospital
Breast Cancer
Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation
Previous studies have shown that the FGF signaling pathway is closely related to endocrine therapy resistance in breast cancer, but there is not sufficient evidence for the combination of endocrine therapy and FGFR inhibitors.
- Trial name
- NCT04936295
- Testing
- Fulvestrant plus Anlotinib
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Sun Yat-sen University
Extranodal NK/T-cell Lymphoma
BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL
This is a randomized, open-label, prospective, multicenter phase III superiority study in patients with newly diagnosed stage IV extranodal NK/T-cell lymphoma.
- Trial name
- BRIDGE-NK (NCT07678229)
- Testing
- GELAD regimen, MEDA regimen, LEAP regimen
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Rong Tao